Oncology Research and Drug Development

Unparalleled Partnership Through
Every Phase of Oncology Research

BioAgilytix is working alongside our pharma and biotech customers to help lead change in the way cancer is treated, looking beyond generic chemotherapies and toward new, more effective personalized approaches. As a bioanalytical CRO specialized in complex drug development efforts, including oncology and immune-oncology studies and trials, we deliver multi-stage bioanalytical services and the extensive expertise needed to add value every step of the way.

Learn More About Our Oncology-Related Experience:

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements with one of our scientists.


The clinical landscape for cancer is currently undergoing an exciting shift. Cancer treatment has historically consisted of surgery, chemotherapy, and radiotherapy, but new therapies have recently emerged as promising weapons in the fight against this terrible disease. For example, antibody drug conjugates (ADCs) use high specificity to bring a tumor-killing agent to its location to eliminate tumor cells only, leaving healthy tissue untouched. Additionally, immuno-oncological approaches are being developed which leverage patients’ own immune systems to eliminate cancer cells, and scientists and doctors are seeing real promise in such targeted therapies.

These molecular and possibly personalized approaches may lead to the dusk of generic chemotherapies and to a new level of curative cancer treatment – and possibly even to the eradication of most types of cancer. However, it takes veteran scientific expertise – and a deep understanding of methods such as mAbs, adoptive cell therapy, immune checkpoint therapy and more – in order to fully realize the potential of such complex biotherapeutics.


Immuno-oncology: Advancing Innovative Therapeutic Options for Treating Human Cancers

There are many extremely promising methods in the realm of immune oncological treatment; this blog post focuses on a few examples that demonstrate the immense power immuno-oncology holds.


To deliver our comprehensive range of services and accurate, reliable, timely data to drive decision-making at every stage of the oncology drug development process, we utilize an array of advanced technologies and platforms.

We apply these technologies strategically and in a tailored fashion to meet the unique assay demands of complex oncology projects. The platforms we most commonly use in oncology-related studies at BioAgilytix include:






Flow Cytometry
(FACS Analysis)

ProteinSimple Ella

LI-COR Odyssey

Download Our Oncolytic Virus Therapies Brochure

See why BioAgilytix is experienced in developing bioanalytical strategies to investigate the mechanisms of oncolytic virus immunotherapies, from their antitumor properties to immune interaction effects.


The development of novel oncological therapeutic tools requires specific and sensitive bioanalytical methods and customized assays, and our veteran scientists have the expertise it takes to advance them. In fact, our scientific team has published more than 100 articles in the oncology arena, showing our commitment to this this area of study.

Trial success also hinges just as much upon researchers and scientists anticipating the addressing every scientific complexity at every stage of the drug development process. We understand that your potentially life-saving cancer therapy is no place for compromises, and work as a partner and true extension of your team to provide thorough expertise in oncology-related bioanalytical research, with the relevant services, technological tools, and techniques you need to make needed advancements for the patients you serve.

If you have a project related to oncology research and development, and would like to learn how BioAgilytix will work to effectively progress it, please speak to our scientific team today.

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Pharmacokinetics & Pharmacodynamics (PK/PD)

    See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.